EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

The transaction includes a $5 cardinal superior infusion of currency oregon equivalent information into MIRA, reinforcing its fiscal presumption and supporting the advancement of SKNY-1, a preclinical-stage oral cause campaigner for value nonaccomplishment and smoking cessation.

Also Read: EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

Under the terms, MIRA volition get SKNY done a banal exchange, whereby SKNY shareholders volition person shares of MIRA communal banal astatine a valuation determined by an autarkic third-party firm.

Additionally, SKNY volition lend $5 cardinal successful currency oregon assets to MIRA astatine closing. Upon completion, SKNY-1 and each related intelligence spot assets volition beryllium afloat integrated into MIRA.

The acquisition of SKNY Pharmaceuticals strategically positions MIRA to participate 2 high-growth pharmaceutical markets with a differentiated, next-generation oral therapy.

• SKNY-1, successful preclinical development, is being investigated arsenic a imaginable oral therapeutic enactment for metabolic regulation. The cause campaigner is designed to interact with cannabinoid receptors CB1 and CB2 pathways that person been demonstrated for their relation successful appetite, metabolism, and vigor equilibrium regulation.

• SKNY-1 is being developed arsenic a imaginable oral therapy that whitethorn enactment by modulating cannabinoid pathways progressive successful nicotine dependence. If successful, it could supply an alternate to existing treatments by addressing cardinal challenges successful smoking cessation.

Last week, MIRA Pharmaceuticals announced the formulation of Ketamir-2 arsenic a topical attraction for localized neuropathic and inflammatory pain.

The advancement expands the company’s symptom absorption portfolio beyond its ongoing Ketamir-2 oral attraction for neuropathic pain.

Price Action: MIRA banal is trading little by 3.12% to $1.24 premarket astatine the past cheque connected Monday.

Read Next:

• Accenture’s Stock Price A Prime Entry Point For Investors, Says Goldman Sachs Analyst

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind marketplace commercialized ideas and tools. Click present to entree unsocial insights that tin acceptable you up successful today's competitory market.

Get the latest banal investigation from Benzinga?

This nonfiction EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug primitively appeared connected Benzinga.com

© 2025 Benzinga.com. Benzinga does not supply concern advice. All rights reserved.